Alzheimer’s

Aduhelm tied to brain swelling in nearly 40% of patients, but few have symptoms, drugmaker says … Operators push back as nursing homes fined nearly $1 million over state vaccination rules … BP drug...

Clinicians should identify strategies to alleviate the social impacts of dementia diagnoses and encourage patients to mobilize informal support networks, researchers say.

Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health

The majority of patients with Alzheimer’s disease would not have been eligible to take part in the clinical trials of the new controversial Alzheimer’s drug  aducanumab (Aduhelm), according...

Older adults who have regular interactions with active listeners are more likely to have cognitive functioning that contradicts evidence of dementia-related brain changes, a new study finds.

The Department of Veterans Affairs has chosen not to include aducanumab (Aduhelm) in its national list of covered drugs, citing risk of adverse events and lack of evidence of positive impact on cognition,...

Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy

The first set of guidelines has been published for clinicians who wish to prescribe the new drug aducanumab (Aduhelm) and to properly monitor its administration. The recommendations fill the gaps between...

Providers will end 2021 better than they started: report … Early-onset dementia prevalence higher than previously estimated, with Alzheimer’s diagnoses leading the surge … Rare COVID-19 vaccine breakthroughs...

Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.